OBOnur Baser

Onur Baser

*This is an algorithmically generated author record based on publicly available information.

Onur Baser has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Network among HTA ecosystem

    by Songul Cinaroglu, Onur Baser

  • Open Access

    Cytoreductive treatment patterns among US veterans with polycythemia vera

    by Shreekant Parasuraman, Jingbo Yu, Dilan Paranagama, Sulena Shrestha, Li Wang, Onur Baser, Robyn Scherber

    Polycythemia vera (PV) is a myeloproliferative neoplasm associated with increased thrombotic and cardiovascular risk, which are key contributors to patient morbidity and mortality. The Veterans Health Administration (VHA) is the largest integrative health network in the United States. Available data concerning patients with PV in this population are limited. This retrospective observational study evaluated the characteristics, management, and outcomes of patients with PV in the VHA Medical SAS® Dataset (October 1, 2005, to September 30, 2012). Inclusion criteria were ≥ 2 claims for PV (ie, PV diagnostic code was recorded) ≥30 days apart during the identification period, age ≥ 18 years, and continuous health plan enrollment from ≥12 months before the index date until the end of follow-up. All data were analyzed using descriptive statistics. The analysis included 7718 patients (median age, 64 years; male, 98%; white, 64%). The most common comorbidities before the index date were hypertension (72%), dyslipidemia (54%), and diabetes (24%); 33% had a history of smoking. During the follow-up period (median, 4.8 years), most patients did not receive treatment with cytoreductive therapy, including phlebotomy (53%), or antiplatelet agents, such as aspirin (57%). The thrombotic and cardiovascular event rates per 1000 patient-years were 60.5 and 83.8, respectively. Among patients who received cytoreductive treatment, the thrombotic event rate was 48.9 per 1000 patient-years. The overall mortality rate was 51.2 per 1000 patient-years. The notable rates of thrombotic and cardiovascular events observed in this analysis, even among patients receiving cytoreductive treatment, highlight the important unmet clinical needs of patients with PV in the VHA.


  • Evaluating treatment patterns of relapsed acute myeloid leukemia (AML) among the elderly in the United States.

    by Qisu Zhang, Lin Xie, Onur Baser, Michael McGuire

    E18161 Background: The type and place of treatment in relapsed AML has not been explored in a large national data set. The goal of this study is to examine treatment patterns among elderly patients (pts) with relapsed AML. Methods: Elderly pts (age ≥ 65 years) with an AML diagnosis (ICD-9-CM: 205.x) were identified using Medicare data from Jan 2010 to Dec 2014. The index date was the first AML treatment date within 30 days of diagnosis. Relapsed pts were identified with ICD-9-CM 205.02 or a claim for AML therapy after a ≥ 120-day treatment-free gap. Pts were required to have continuous enrollment 12 months before AML diagnosis and 6 months after, and no pre-diagnosis claims for blood cancer, chemotherapy, radiotherapy, or AML-related surgery. Transfusion dependence (TD) was defined as ≥ 2 transfusions within an 8-week period. The type and place of treatment for relapsed pts with both 1st- and 2nd-line therapy was examined. Results: 1,726 pts who received treatment for relapsed AML were included in the study. The 30- and 60-day mortality rates from the date of relapse treatment were 19.6% and 33.6%. During 1st-line therapy, 28.6% of pts received inpatient chemotherapy only, 59.1% received both inpatient and outpatient therapy (median inpatient length of stay [LOS]: 32 days), and 3.8% received outpatient therapy only. The most frequent outpatient therapies were hypomethylating agents and supportive therapies, e.g. G-CSF, anti-infectives. 11.3% of inpatients were given a bone marrow transplant (BMT). Additionally, 90.1% of pts received blood transfusions at an average rate of 8.9 per year, and 77.2% of pts were TD. During 2nd-line therapy, 19.6% of relapsed pts received inpatient chemotherapy only, 41.2% received both inpatient and outpatient therapy (median inpatient LOS: 7 days), and 9.3% received outpatient therapy only. Outpatient therapies were similar to those seen at 1st line. 10.3% of inpatients were given a BMT. 80.9% of pts received blood transfusions at an average rate of 19.7 per year, and 60.4% of pts were TD. Conclusions: Current treatment options available for relapsed AML pts are associated with a significant treatment burden at both 1st and 2nd lines of therapy, as well as a high early-mortality rate.


  • First-line chemotherapy (CT) versus anti-androgen therapy (AT) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Individual patient analysis of the Veterans Health Administration (VHA) dataset.

    by Guru Sonpavde, Ahong Huang, Li Wang, Onur Baser, Raymond Miao

    156 Background: The outcomes of pts receiving first-line CT vs AT for mCRPC are unclear. Using the VHA dataset, we compared outcomes with first-line CT vs AT in pts with mCRPC and assessed the impact of prior androgen deprivation therapy (ADT) duration and known prognostic factors. Methods: Pts with mCRPC initiating first-line AT (abiraterone, enzalutamide) or CT (taxane) from Oct 2012 to Sept 2014 were identified. The impact of AT vs CT on overall survival (OS) and time to discontinuation (TTD) was assessed using Cox proportional hazard models, adjusting for prior ADT duration, known prognostic factors (hemoglobin [Hb], albumin [alb], alkaline phosphatase [ALP], prostate-specific antigen [PSA]), Charlson Comorbidity Index (CCI) and chronic disease score (CDS). Results: Overall, 1445 pts were evaluable; 1108 received AT (abiraterone 996, enzalutamide 112) and 337 received CT (docetaxel). The overall median duration of prior ADT was 464 days. On multivariable analysis, prior ADT duration, CCI, CDS, Hb, Alb, ALP and PSA were associated with OS, but AT vs CT was not (HR: 1.041 [95% CI: 0.853–1.270], p = 0.6943). PSA levels, prior ADT duration, and ALP was associated with TTD, and TTD was shorter for CT vs AT (HR: 2.339 [95% CI: 1.969–2.779], p < 0.0001). Longer prior ADT duration was associated with longer OS (HR: 0.566, p < 0.0001) and TTD (HR: 0.831, p = 0.0363) in the AT cohort, but not in the CT cohort. Treatment-free interval (TFI) (between first- and second-line treatment) was longer for CT vs AT (mean: 53 vs 39 days; p = 0.0303). Conclusions: To our knowledge, this is one of the largest mCRPC datasets analyzed at the individual pt level comparing first-line CT vs AT. OS was not significantly different for first-line CT vs AT after adjusting for key prognostic factors, despite shorter TTD with CT and longer TFI after first-line CT. Prior ADT duration ≤ 464 days was associated with shorter OS and TTD in the AT cohort, but not the CT cohort, suggesting that such pts may benefit from receiving CT over AT. The results are hypothesis-generating and prospective validation is required. Funding: Sanofi Genzyme


  • External validation of a claims-based and clinical approach for predicting post-pulmonary embolism outcomes among United States veterans

    by Christine G. Kohn, Erin R. Weeda, Neela Kumar, Philip S. Wells, W. Frank Peacock, Gregory J. Fermann, Li Wang, Onur Baser, Jeff R. Schein, Concetta Crivera, et al.

    The In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) rule can accurately identify pulmonary embolism (PE) patients at low risk of early complications using claims data. We sought to externally validate the IMPACT and simplified Pulmonary Embolism Severity Index (sPESI) tools for predicting all-cause mortality and readmission. We used Veteran Health Administration data (10/1/2010–9/30/2015) to identify adults with ≥1 inpatient diagnosis code for acute PE, ≥12 months continuous medical and pharmacy benefits prior to the index PE, ≥90 days of post-event follow-up (unless death occurred) and ≥1 claim for an anticoagulant during the index PE stay. Prognostic accuracies of IMPACT and sPESI for 30- and 90-day all-cause mortality and 90-day readmission were estimated. Of 6,746 PE patients, 7.5 and 12.6% died at 30 and 90 days. Within 90 days, 20.1% were readmitted for any reason. Hospitalization for recurrent VTE and major bleeding occurred in 5.6 and 1.7% of patients. IMPACT classified 15.2% as low risk, while 28.4% were low risk per sPESI. Both tools displayed sensitivity >90% and negative predictive values (NPVs) >97% for 30-day mortality, but low specificity (range 16.2–30.0) and positive predictive values (PPVs) (range 8.7–9.5); with similar results observed for 90-day mortality. IMPACT’s sensitivity for all-cause readmission was numerically higher than sPESI (88.2 vs. 79.0%), but both had comparable NPVs (85.1 vs. 84.2%). Similar trends were observed for VTE or major bleeding readmissions. IMPACT classified patients for post-PE outcomes with similar accuracy as sPESI. IMPACT appears useful for identifying PE patients at low risk for early mortality or readmission in claims-based studies.


  • Open Access

    Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: a retrospective cohort study

    by Kathleen M. Fox, Li Wang, Shravanthi R. Gandra, Ruben G. W. Quek, Lu Li, Onur Baser

    Annual direct costs for cardiovascular (CV) diseases in the United States are approximately $195.6 billion, with many high-risk patients remaining at risk for major cardiovascular events (CVE). This study evaluated the direct clinical and economic burden associated with new CVE up to 3 years post-event among patients with hyperlipidemia. Hyperlipidemic patients with a primary inpatient claim for new CVE (myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, coronary artery bypass graft, percutaneous coronary intervention and heart failure) were identified using IMS LifeLink PharMetrics Plus data from January 1, 2006 through June 30, 2012. Patients were stratified by CV risk into history of CVE, modified coronary heart disease risk equivalent, moderate- and low-risk cohorts. Of the eligible patients, propensity score matched 243,640 patients with or without new CVE were included to compare healthcare resource utilization and direct costs ranging from the acute (1-month) phase through 3 years post-CVE date (follow-up period). Myocardial infarction was the most common CVE in all the risk cohorts. During the acute phase, among patients with new CVE, the average incremental inpatient length of stay and incremental costs ranged from 4.4–6.2 days and $25,666–$30,321, respectively. Acute-phase incremental costs accounted for 61–75 % of first-year costs, but incremental costs also remained high during years 2 and 3 post-CVE. Among hyperlipidemic patients with new CVE, healthcare utilization and costs incurred were significantly higher than for those without CVE during the acute phase, and remained higher up to 3 years post-event, across all risk cohorts.


    • 2 August 2015
      • p. 1-9

    The economic impact of symptomatic menopause among low-socioeconomic women in the United States.

    by Allison Keshishian, Yuexi Wang, Lin Xie, Onur Baser

    Menopausal symptoms have a significant negative impact on patient's quality of life and increase healthcare costs among women. This retrospective analysis used data from a U.S. national database (01 January 2008-31 December 2010). Patients with a diagnosis of menopause symptoms or a prescription claim for hormone therapy were matched to control patients. Healthcare resource utilization and costs during the 6-month follow-up period were compared. Generalized linear models were used to adjust for differences in baseline and demographic characteristics between the cohorts. A total of 71,076 patients were included in each cohort. Patients with menopausal symptoms were more likely to have depression and anxiety and incurred significantly higher follow-up healthcare costs ($7237 vs $6739, p < 0.001) and healthcare utilization during the 6-month follow-up period. Patients diagnosed with menopausal symptoms or treated with hormone therapy incurred significantly higher healthcare costs than those without menopausal symptoms or treatment.

  • The economic impact of symptomatic menopause among low-socioeconomic women in the United States

    by Allison Keshishian, Yuexi Wang, Lin Xie, Onur Baser

    Background: Menopausal symptoms have a significant negative impact on patient’s quality of life and increase healthcare costs among women. Methods: This retrospective analysis used data from a U.S. national database (01 January 2008–31 December 2010). Patients with a diagnosis of menopause symptoms or a prescription claim for hormone therapy were matched to control patients. Healthcare resource utilization and costs during the 6-month follow-up period were compared. Generalized linear models were used to adjust for differences in baseline and demographic characteristics between the cohorts. Results: A total of 71,076 patients were included in each cohort. Patients with menopausal symptoms were more likely to have depression and anxiety and incurred significantly higher follow-up healthcare costs ($7237 vs $6739, p < 0.001) and healthcare utilization during the 6-month follow-up period. Conclusion: Patients diagnosed with menopausal symptoms or treated with hormone therapy incurred significantly higher healthcare costs than those without menopausal symptoms or treatment.